Uncommon gastrointestinal complications after liver transplantation: Radiologic findings and clinical features

2013 ◽  
Vol 54 (1) ◽  
pp. 1-7
Author(s):  
Heon-Ju Kwon ◽  
Kyoung Won Kim ◽  
Gi-Won Song ◽  
Shin Hwang ◽  
Hyun Kwon Ha ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Early Detection ◽  
Clinical Features ◽  
Early Treatment ◽  
Liver Diseases ◽  
Gastrointestinal Complications ◽  
Radiologic Findings ◽  
End Stage ◽  
Radiologic Features

There are various uncommon gastrointestinal complications, as liver transplantation becomes increasingly popular as the only curative method for patients with end-stage liver diseases. It is important for radiologists evaluating postoperative liver transplantation recipients to have a perspective on the possible gastrointestinal complications after liver transplantation and their radiologic features for early detection and early treatment. This article illustrates radiologic findings and clinical features of various uncommon gastrointestinal complications after liver transplantation.

scholarly journals Stem Cell-Related Studies and Stem Cell-Based Therapies in Liver Diseases

2019 ◽  
Vol 28 (9-10) ◽  
pp. 1116-1122 ◽  
Author(s):  
Wei Zhou ◽  
Erek D. Nelson ◽  
Anan A. Abu Rmilah ◽  
Bruce P. Amiot ◽  
Scott L. Nyberg
Keyword(s):  
Liver Transplantation ◽  
Stem Cell ◽  
Liver Disease ◽  
Liver Failure ◽  
Effective Treatment ◽  
Liver Diseases ◽  
Immunosuppressive Agents ◽  
End Stage Liver Disease ◽  
Effective Interventions ◽  
End Stage

Owing to the increasing worldwide burden of liver diseases, the crucial need for safe and effective interventions for treating end-stage liver failure has been a very productive line of inquiry in the discipline of hepatology for many years. Liver transplantation is recognized as the most effective treatment for end-stage liver disease; however, the shortage of donor organs, high medical costs, and lifelong use of immunosuppressive agents represent major drawbacks and demand exploration for alternative treatments. Stem cell-based therapies have been widely studied in the field of liver diseases and are considered to be among the most promising therapies. Herein, we review recent advances in the application of stem cell-related therapies in liver disease with the aim of providing readers with relevant knowledge in this field and inspiration to spur further inquiry.

scholarly journals Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 386 ◽  
Author(s):  
Viviana Cernigliaro ◽  
Rossella Peluso ◽  
Beatrice Zedda ◽  
Lorenzo Silengo ◽  
Emanuela Tolosano ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Transplantation ◽  
Extracellular Vesicles ◽  
Liver Diseases ◽  
Adult Stem Cells ◽  
Embryonic Stem ◽  
Hepatic Function ◽  
Bioactive Molecules ◽  
Cell Based Therapy ◽  
End Stage

Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases.

[141] LONG TERM FOLLOW-UP OF LIVER TRANSPLANTATION (OLT) FOR CHOLESTATIC AND AUTOIMMUNE END STAGE LIVER DISEASES

2007 ◽  
Vol 46 ◽  
pp. S63-S64
Author(s):  
L. Blasone ◽  
S. Fagiuoli ◽  
M. Colledan ◽  
M. Strazzabosco ◽  
M. Lenzi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Diseases ◽  
Long Term Follow Up ◽  
End Stage

scholarly journals Rare cause of non-immune hemolytic anemia in end-stage liver disease

2020 ◽  
Vol 7 (2) ◽  
pp. 7
Author(s):  
Maheep Singh Sangha ◽  
Aakash Aggarwal ◽  
Japmehr Sandhu
Keyword(s):  
Liver Transplantation ◽  
Liver Diseases ◽  
Cell Formation ◽  
Decompensated Cirrhosis ◽  
Severe Anemia ◽  
Multidrug Therapy ◽  
Bile Acid Sequestrants ◽  
End Stage Liver Disease ◽  
Immune Hemolytic Anemia ◽  
End Stage

Spur cells are reportedly linked to advanced end-stage liver diseases and may lead to accelerated hemolysis. In this case report, we discuss one of these rare instances when a 45-year-old female with decompensated cirrhosis was admitted for severe anemia. Extensive workup revealed non-immune hemolysis secondary to spur cell formation. Orthotopic liver transplantation remains the only treatment of choice for reversal of spur cell anemia. Alternatively, multidrug therapy has also been explored, including usage of bile acid sequestrants; however, success is rare.

Outcomes of Orthotopic Liver Transplantation in Non-malignant End-stage Liver Diseases

2014 ◽  
Vol 46 (3) ◽  
pp. 778-781 ◽  
Author(s):  
Y. Sirivatanauksorn ◽  
N. Kongkaewpaisan ◽  
A. Pongpaibul ◽  
S. Limsrichamrern ◽  
P. Mahawithitwong ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Liver Diseases ◽  
End Stage

Lipid and apolipoprotein changes after orthotopic liver transplantation for end-stage liver diseases

1992 ◽  
Vol 209 (3) ◽  
pp. 169-177 ◽  
Author(s):  
Claude L. Malmendier ◽  
Jean-F. Lontie ◽  
Denis Mathé ◽  
René Adam ◽  
Henri Bismuth
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Liver Diseases ◽  
End Stage

scholarly journals Heterogenic transplantation of bone marrow-derived rhesus macaque mesenchymal stem cells ameliorates liver fibrosis induced by carbon tetrachloride in mouse

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e4336 ◽  
Author(s):  
Xufeng Fu ◽  
Bin Jiang ◽  
Bingrong Zheng ◽  
Yaping Yan ◽  
Junfeng Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Liver Transplantation ◽  
Mesenchymal Stem Cells ◽  
Carbon Tetrachloride ◽  
Liver Fibrosis ◽  
Liver Diseases ◽  
Pathological Examination ◽  
Paracrine Effects ◽  
End Stage

Liver fibrosis is a disease that causes high morbidity and has become a major health problem. Liver fibrosis can lead to the end stage of liver diseases (livercirrhosisand hepatocellularcarcinoma). Currently, liver transplantation is the only effective treatment for end-stage liver disease. However, the shortage of organ donors, high cost of medical surgery, immunological rejection and transplantation complications severely hamper liver transplantation therapy. Mesenchymal stem cells (MSCs) have been regarded as promising cells for clinical applications in stem cell therapy in the treatment of liver diseases due to their unique multipotent differentiation capacity, immunoregulation and paracrine effects. Although liver fibrosis improvements by MSC transplantation in preclinical experiments as well as clinical trials have been reported, the in vivo fate of MSCs after transportation and their therapeutic mechanisms remain unclear. In this present study, we isolated MSCs from the bone marrow of rhesus macaques. The cells exhibited typical MSC markers and could differentiate into chondrocytes, osteocytes, and adipocytes, which were not affected by labeling with enhanced green fluorescent protein (EGFP). The harvested MSCs respond to interferon-γ stimulation and have the ability to inhibit lymphocyte proliferation in vitro. EGFP-labeled MSCs (1 × 106 cells) were transplanted into mice with carbon tetrachloride-induced liver fibrosis via tail vein injection. The ability of the heterogenic MSC infusion to ameliorate liver fibrosis in mice was evaluated by a blood plasma chemistry index, pathological examination and liver fibrosis-associated gene expression. Additionally, a small number of MSCs that homed and engrafted in the mouse liver tissues were evaluated by immunofluorescence analysis. Our results showed that the transplantation of heterogenic MSCs derived from monkey bone marrow can be used to treat liver fibrosis in the mouse model and that the paracrine effects of MSCs may play an important role in the improvement of liver fibrosis.

Sign in / Sign up

Export Citation Format

Share Document